Romo Eduardo Z, Zivkovic Angela M
Department of Nutrition, University of California, Davis, Davis, CA, United States.
Front Cardiovasc Med. 2022 May 27;9:928566. doi: 10.3389/fcvm.2022.928566. eCollection 2022.
High-density lipoprotein (HDL) particles, long known for their critical role in the prevention of cardiovascular disease (CVD), were recently identified to carry a wide array of glycosylated proteins, and the importance of this glycosylation in the structure, function and metabolism of HDL are starting to emerge. Early studies have demonstrated differential glycosylation of HDL-associated proteins in various pathological states, which may be key to understanding their etiological role in these diseases and may be important for diagnostic development. Given the vast array and specificity of glycosylation pathways, the study of HDL-associated glycosylation has the potential to uncover novel mechanisms and biomarkers of CVD. To date, no large studies examining the relationships between HDL glycosylation profiles and cardiovascular outcomes have been performed. However, small pilot studies provide promising preliminary evidence that such a relationship may exist. In this review article we discuss the current state of the evidence on the glycosylation of HDL-associated proteins, the potential for HDL glycosylation profiling in CVD diagnostics, how glycosylation affects HDL function, and the potential for modifying the glycosylation of HDL-associated proteins to confer therapeutic value.
高密度脂蛋白（HDL）颗粒长期以来因其在预防心血管疾病（CVD）中的关键作用而闻名，最近被发现携带多种糖基化蛋白，并且这种糖基化在HDL的结构、功能和代谢中的重要性正开始显现出来。早期研究已经证明，在各种病理状态下，HDL相关蛋白存在差异糖基化，这可能是理解它们在这些疾病中的病因学作用的关键，并且可能对诊断发展很重要。鉴于糖基化途径的多样性和特异性，对HDL相关糖基化的研究有可能揭示CVD的新机制和生物标志物。迄今为止，尚未进行过大型研究来检验HDL糖基化谱与心血管结局之间的关系。然而，小型试点研究提供了有前景的初步证据，表明这种关系可能存在。在这篇综述文章中，我们讨论了HDL相关蛋白糖基化的现有证据状态、HDL糖基化谱在CVD诊断中的潜力、糖基化如何影响HDL功能，以及修饰HDL相关蛋白的糖基化以赋予治疗价值的潜力。
